ACH 36

Drug Profile

ACH 36

Alternative Names: ACH36

Latest Information Update: 06 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ache Laboratories
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anxiety disorders

Most Recent Events

  • 31 Dec 2014 ACH 36 is still in preclinical trials for Anxiety disorders in Brazil (Ache Laboratories' annual report,
  • 31 Dec 2013 Preclinical trials in Anxiety disorders in Brazil prior to December (unspecified route) (Ache Laboratories' annual report,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top